



## MEDIA RELEASE

### **\$3.0m CRC-P grant to VivaZome Therapeutics and Partners for Customised Exosome Therapy**

**Collaboration with La Trobe University, The University of Queensland,  
Australian National University, Cytiva and SeerPharma Pty Ltd**

**19 January 2023 - Melbourne, Australia:** VivaZome Therapeutics Pty Ltd (“VivaZome”) is delighted to announce that it has been awarded an Australian Government Round 13 CRC-P grant of \$3.0m in support of the project “Customised exosomes - the future of regenerative medicine”.

The Hon Ed Husic MP, Minister for Industry and Science, who oversees the Cooperative Research Centre Projects (CRC-P) Grants Scheme announced the successful Round 13 applications today. The scheme supports the development of innovative Australian companies and sectors, and promotes collaboration between small companies, large companies and academic institutions.

Joining VivaZome in the CRC-P are five Australian project partners, bringing high-level scientific, technical and operational capability to the 3–year project. The partner organisations and the key project leaders at each are:

- La Trobe University: Dr Lesley Cheng, Group Leader, Neurodegeneration Biology and Biomarker Group, La Trobe Institute for Molecular Sciences (LIMS)
- The University of Queensland: Professor David Reutens, Director of the Centre for Advanced Imaging
- Australian National University: Professor Riccardo Natoli, Group Leader - Clear Vision Research
- Cytiva: Professor Tim O’Meara, Strategy Manager - Government & Research, ANZ
- SeerPharma Pty Ltd: Mr Paul Kerr, Director

Dr David Haylock, CEO of VivaZome said: “We are absolutely delighted to receive this strong support from the Australian Government, and to be working with an incredible group of world-leading project partners. Exosomes have great potential to treat a wide range of diseases, including traumatic brain injury and retinal disease. With the help of our partner organisations, we will establish an exosome manufacturing facility, optimise technologies and processes for manufacture of exosomes, develop customised exosome products with enhanced function, and generate proof of concept data for clinical indications in areas of significant unmet need – ophthalmic and neurological diseases.”

The VivaZome CRC-P project work commences in early 2023 with a series of significant scientific, industrial and education milestones to be achieved by the end of 2025.

For further information, contact:

Dr David Haylock, CEO, VivaZome Therapeutics Pty Ltd

[David.haylock@vivazome.com](mailto:David.haylock@vivazome.com)

Phone: +61 (0) 439 617 657

**About VivaZome:**

VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, with operational headquarters at the La Trobe University Technology Enterprise Centre in Melbourne, Australia. VivaZome aims to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies and generating intellectual property that are applicable generically to exosome therapies. These will underpin the Company's development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

For more information, please visit [www.vivazome.com](http://www.vivazome.com)